Journal article
Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor
IJG Burvenich, W Farrugia, FT Lee, B Catimel, Z Liu, D Makris, D Cao, GJ O'Keefe, MW Brechbiel, D King, V Spirkoska, LC Allan, PA Ramsland, AM Scott
Mabs | Published : 2016
Abstract
IgG has a long half-life through engagement of its Fc region with the neonatal Fc receptor (FcRn). The FcRn binding site on IgG1 has been shown to contain I253 and H310 in the CH2 domain and H435 in the CH3 domain. Altering the half-life of IgG has been pursued with the aim to prolong or reduce the half-life of therapeutic IgGs. More recent studies have shown that IgGs bind differently to mouse and human FcRn. In this study we characterize a set of hu3S193 IgG1 variants with mutations in the FcRn binding site. A double mutation in the binding site is necessary to abrogate binding to murine FcRn, whereas a single mutation in the FcRn binding site is sufficient to no longer detect binding to h..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported in part by Operational Infrastructure Support Program funding provided by the Victorian Government, Ludwig Research Institute and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This research was supported by NHMRC Project Grants 542512, 1030469, NHMRC Practitioner Fellowship (A.M.S), and NHMRC Program grant 487922.